 "Fresh triggers kick in for Natco, market share gains for copaxone drug")
Natco Pharma, which had fallen sharply by 20 per cent in the past one month, and is currently trading near its 52-week lows, surged over six per cent on Monday. These gains follow a favourable judgment by a US court with respect to copaxone drug, and is among the last few patent infringement cases Natco's partner Mylan is defending. With this, and a good show expected in the second half of 2018-19, there could be more gains ahead for Natco, which is among top domestic drug makers that also exports to global markets.
The latest news also eases earlier concerns
